Back to search

Article

Risk stratification by minimal residual disease detection and ctDNA dynamics from personalised assays in stage II-III colorectal cancer in a UK multi-centre prospective study (TRACC Part B)

2026-02-10

Abstract excerpt

<title>Abstract</title> <p> Background Circulating tumour DNA (ctDNA) detects minimal residual disease (MRD) and predicts recurrence in resected colorectal cancer (CRC), with implications for adjuvant chemotherapy (ACT) decision-making. Longitudinal ctDNA quantification and dynamics are less well studied. We present results from the ongoing prospective multi-centre TRACC study using a tumour-informed ctDNA assa...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
21604043-8be3-57b2-b630-1c13de791f4d
DOI
10.21203/rs.3.rs-8574150/v1
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Risk stratification by minimal residual disease detection and ctDNA dynamics from personalised assays in stage II-III colorectal cancer in a UK multi-centre prospective study (TRACC Part B)DOI 10.21203/rs.3.rs-8574150/v1
Tissue-Free Liquid Biopsies Combining Genomic and Methylation Signals for Minimal Residual Disease Detection in Patients with Early Colorectal Cancer from the UK TRACC Part B Study.Semantic proximity
Analysis of Plasma Cell-Free DNA by Ultradeep Sequencing in Patients With Stages I to III Colorectal CancerSemantic proximity
Serial circulating tumour DNA analysis during multimodality treatment of locally advanced rectal cancer: a prospective biomarker study.Semantic proximity
Personalised circulating tumour DNA assay with large-scale mutation coverage for sensitive minimal residual disease detection in colorectal cancer.Semantic proximity
Detection of circulating tumor DNA by tumor-informed whole-genome sequencing enables prediction of recurrence in stage III colorectal cancer patients.Semantic proximity
Ultrasensitive tumour‐agnostic non‐invasive detection of colorectal cancer recurrence using ctDNA methylationSemantic proximity
Molecular residual disease detection by serial tumour-informed circulating tumour DNA analysis in resectable oesophageal & gastroesophageal junctional adenocarcinoma: a prospective UK multi-centre studySemantic proximity
Using ctDNA to Predict Recurrence After Surgery in Stage II–III Colorectal Cancer: A Systematic Review and Narrative Meta-AnalysisSemantic proximity
Minimal residual disease in colorectal cancer. Tumor-informed versus tumor-agnostic approaches: unraveling the optimal strategy.Semantic proximity
Targeted next-generation sequencing of circulating-tumor DNA for tracking minimal residual disease in localized colon cancerSemantic proximity
Dynamic monitoring of circulating tumor DNA to predict prognosis and efficacy of adjuvant chemotherapy after resection of colorectal liver metastases.Semantic proximity
Finding Waldo: The Evolving Paradigm of Circulating Tumor DNA (ctDNA)-Guided Minimal Residual Disease (MRD) Assessment in Colorectal Cancer (CRC)Semantic proximity
Select a neighboring publication to make it the new centre.